Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801870 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRKMT2ALMNAFKBP1A | |
| SCHEMBL23249892 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRKMT2ALMNAFKBP1A | |
| SCHEMBL16653935 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRKMT2ALMNAFKBP1A | |
| SCHEMBL23249940 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRKMT2ALMNAFKBP1A | |
| SCHEMBL17005427 | 0.87 | LMNA (0.46) | SMN1; SMN2LMNAHRH4HRH3L3MBTL1 | |
| SCHEMBL3128357 | 0.87 | LMNA (0.46) | SMN1; SMN2LMNAHRH4HRH3L3MBTL1 | |
| SCHEMBL2806983 | 0.87 | LMNA (0.46) | SMN1; SMN2LMNAHRH4HRH3L3MBTL1 | |
| SCHEMBL16633219 | 0.86 | JAK2 (0.41) | SMN1; SMN2TSHRKMT2ALMNAMEN1 | |
| SCHEMBL19829019 | 0.86 | JAK2 (0.41) | SMN1; SMN2TSHRKMT2ALMNAMEN1 | |
| SCHEMBL29874101 | 0.86 | JAK2 (0.41) | SMN1; SMN2TSHRKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | SMN1; SMN2 3299/4885TSHR 3185/4885KMT2A 1852/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | SMN1; SMN2 3299/4885TSHR 3185/4885KMT2A 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.